Estrogen (ER) and progesterone receptor (PgR) status was determined in 41 women with operable endometrial cancer before and after administration of tamoxifen (TAM). The first sample was obtained by hysteroscopy to ensure a precise biopsy of neoplastic tissue; the second was done on the surgical specimen. PgR content was significantly increased after TAM treatment and this data was compared with the degree of tumor differentiation.
LucianiL., OrianaS., SpattiG.B.. Hormonal and receptor status in postmenopausal women with endometrial carcinoma before and after treatment with tamoxifen.Tumori1984; 70: 189–92.
2.
MortelR., LevyC., WolffJ.P.Female sex steroid receptors in postmenopausal endometrial carcinoma and biochemical response to an antiestrogen.Cancer Res1981; 41: 140–7.
3.
KatzenellenbogenR.S., MillerM.A., MullikA., SheenY.Y.Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites.Breast Cancer Res and Treat1985; 5: 231–43.
4.
NeumannovaM., KauppilaA., VinkoR.Cytosol and nuclear estrogen and progestin receptors and 17-beta-hydroxysteroid dehydrogenase activity in normal and carcinomatous endometrium.Obstet Gynecol1983; 61, 2: 181–8.
5.
KauppilaA.J., IsotaloH.E., KivinenS.T.Prediction of clinical outcome with estrogen and progestin receptor concentrations and their relationship to clinical and histopathologic variables in endometrial carcinoma.Cancer Res1986; 46, 10: 5380–4.
6.
BonteJ., De CosterJ.M., IdeP., BillietG.Hormo-noprophylaxis and hormonotherapy in the treatment of endometrial adenocarcinoma by means of medroxyprogesterone acetate.Gynecol Oncol1978; 6: 60–6.
7.
De PaloG., SpattiG.B., BandieramonteG., LucianiL.Pilot study with adjuvant hormone therapy in FIGO stage I endometrial carcinoma with myometrial invasion.Tumori1983; 69: 65–9.
8.
De PaloG., KendaR., AndreolaS., MusumeciR, RilkeF.Endometrial carcinoma stage I: a retrospective analysis of 262 patients.Obstet Gynecol1982; 60: 225–34.
9.
De PaloG., MarubiniE., Del VecchioM.Adjuvant treatment with medroxyprogesterone acetate in pathologic stage I endometrial carcinoma with myometrial invasion: preliminary analysis of multicentre clinical trial. In: Ballon, Racinet, Vrausas, eds. Endometrial Cancer - Basel: Karger, 1986; 209–22.
10.
SwenertonK.D.Treatment of advanced endometrial adenocarcinoma with tamoxifen.Cancer Treatment Reports1980; 64: 805–11.
11.
HaldI., SalimtschikM.Tamoxifen treatment of advanced endometrial carcinoma - A phase II study.Eur J Gynecol Oncol1983; 4: 2–12.
12.
Dell'AcquaS., IacobelliS., De Cicco NardoneF.Sequential tamoxifen and medroxyprogesterone acetate vs. tamoxifen in the treatment of endometrial cancer. International Symposium of Hormonotherapy and Anti-estrogens in Oncology, Bologna 1985; 6-8 June.
13.
HaldI., PagerJ., SalimtschikM., MouridsenH.T.Tamoxifen treatment of advanced endometrial carcinoma: a phase II study.Reviews on Endocrine-Related Cancer II (suppl): 1982; 43–6.
14.
SwenertonK.D.Experience with tamoxifen in endometrial cancer.Reviews on Endocrine - Related Cancer II (suppl) 1982; 47–9.
15.
TsengL., ManzellaJ., FuntM.I.Preliminary studies of aromatase in human neoplastic endometrium.Obstet Gynecol1984; 63, 2: 150–4.
16.
SledgeG.W., RanzyI., DresslerG.D.Presence of an estrogen-regulated protein in endometrial cancer.Obstet Gynecol1985; 66, 3: 423–7.
